BACKGROUND AND AIMS: As integral membrane proteins, claudins form tight junctions together with occludin. Several claudins were shown to be up-regulated in various cancer types. We performed an expression analysis of genes encoding tight junction proteins to display differential gene expression on RNA and protein level and to identify and validate potential targets for colorectal cancer (CRC) therapy. PATIENTS AND METHODS: Amplified and biotinylated cRNA from 30 microdissected CRC specimen and corresponding normal tissues was hybridized to Affymetrix U133set GeneChips. Quantification of differential protein expression of claudin-1, -8 and -12 between normal and corresponding tumour tissues was performed by Western blot analyses. Paraffin-embedded CRC tissue samples, colon cancer cell lines and normal tissue microarray were analysed for protein expression of claudin-1 by immunohistochemistry (IHC). RESULTS: Claudin-1 (CLDN1) and -12 (CLDN12) are frequently overexpressed in CRC, whereas claudin-8 (CLDN8) shows down-regulation in tumour tissue on RNA level. Quantification of proteins confirmed the overexpression of claudin-1 in tumour tissues, whereas changes of claudin-8 and -12 were not significantly detectable on protein level. IHC confirmed the markedly elevated expression level of claudin-1 in the majority of CRC, showing membranous and intracellular vesicular staining. CONCLUSIONS: Differential expression of genes encoding claudins in CRC suggests that these tight junction proteins may be associated to and involved in tumorigenesis. CLDN1 is frequently up-regulated in large proportion of CRC and may represent potential target molecule for blocking studies in CRC.
BACKGROUND AND AIMS: As integral membrane proteins, claudins form tight junctions together with occludin. Several claudins were shown to be up-regulated in various cancer types. We performed an expression analysis of genes encoding tight junction proteins to display differential gene expression on RNA and protein level and to identify and validate potential targets for colorectal cancer (CRC) therapy. PATIENTS AND METHODS: Amplified and biotinylated cRNA from 30 microdissected CRC specimen and corresponding normal tissues was hybridized to Affymetrix U133set GeneChips. Quantification of differential protein expression of claudin-1, -8 and -12 between normal and corresponding tumour tissues was performed by Western blot analyses. Paraffin-embedded CRC tissue samples, colon cancer cell lines and normal tissue microarray were analysed for protein expression of claudin-1 by immunohistochemistry (IHC). RESULTS:Claudin-1 (CLDN1) and -12 (CLDN12) are frequently overexpressed in CRC, whereas claudin-8 (CLDN8) shows down-regulation in tumour tissue on RNA level. Quantification of proteins confirmed the overexpression of claudin-1 in tumour tissues, whereas changes of claudin-8 and -12 were not significantly detectable on protein level. IHC confirmed the markedly elevated expression level of claudin-1 in the majority of CRC, showing membranous and intracellular vesicular staining. CONCLUSIONS: Differential expression of genes encoding claudins in CRC suggests that these tight junction proteins may be associated to and involved in tumorigenesis. CLDN1 is frequently up-regulated in large proportion of CRC and may represent potential target molecule for blocking studies in CRC.
Authors: Joern Groene; Ulrich Mansmann; Reinhard Meister; Eike Staub; Stefan Roepcke; Maya Heinze; Irina Klaman; Thomas Brümmendorf; Klaus Hermann; Christoph Loddenkemper; Christian Pilarsky; Benno Mann; Hans-Peter Adams; Heinz Johannes Buhr; André Rosenthal Journal: Int J Cancer Date: 2006-10-15 Impact factor: 7.396
Authors: Ala-Eddin Al Moustafa; Moulay A Alaoui-Jamali; Gerald Batist; Maite Hernandez-Perez; Corinne Serruya; Lesley Alpert; Martin J Black; Robert Sladek; William D Foulkes Journal: Oncogene Date: 2002-04-18 Impact factor: 9.867
Authors: Viola A Heinzelmann-Schwarz; Margaret Gardiner-Garden; Susan M Henshall; James Scurry; Richard A Scolyer; Michael J Davies; Matthias Heinzelmann; Larry H Kalish; Anish Bali; James G Kench; Lyndal S Edwards; Patricia M Vanden Bergh; Neville F Hacker; Robert L Sutherland; Philippa M O'Brien Journal: Clin Cancer Res Date: 2004-07-01 Impact factor: 12.531
Authors: S T Mees; R Mennigen; T Spieker; E Rijcken; N Senninger; J Haier; M Bruewer Journal: Int J Colorectal Dis Date: 2009-01-29 Impact factor: 2.571
Authors: Christopher S Williams; Baolin Zhang; J Joshua Smith; Ashwath Jayagopal; Caitlyn W Barrett; Christopher Pino; Patricia Russ; Sai H Presley; DunFa Peng; Daniel O Rosenblatt; Frederick R Haselton; Jin-Long Yang; M Kay Washington; Xi Chen; Steven Eschrich; Timothy J Yeatman; Wael El-Rifai; R Daniel Beauchamp; Min S Chang Journal: J Clin Invest Date: 2011-09-12 Impact factor: 14.808
Authors: Mateusz Bujko; Paulina Kober; Michal Mikula; Marcin Ligaj; Jerzy Ostrowski; Janusz Aleksander Siedlecki Journal: Oncol Lett Date: 2015-04-08 Impact factor: 2.967
Authors: Ágnes Holczbauer; Benedek Gyöngyösi; Gábor Lotz; Attila Szijártó; Péter Kupcsulik; Zsuzsa Schaff; András Kiss Journal: J Histochem Cytochem Date: 2013-02-05 Impact factor: 2.479
Authors: Vesela P Kovacheva; Jessica M Davison; Tiffany J Mellott; Adrianne E Rogers; Shi Yang; Michael J O'Brien; Jan Krzysztof Blusztajn Journal: FASEB J Date: 2008-12-01 Impact factor: 5.191
Authors: Rachel E Mellas; Noel J Leigh; Joel W Nelson; Andrew D McCall; Olga J Baker Journal: J Histochem Cytochem Date: 2014-09-23 Impact factor: 2.479